MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals International, plc
NASDAQ
77.83
-0.32
-0.41%
After Hours: 77.83 0 0.00% 16:10 08/13 EDT
OPEN
78.65
PREV CLOSE
78.15
HIGH
79.69
LOW
77.20
VOLUME
451.32K
TURNOVER
--
52 WEEK HIGH
82.94
52 WEEK LOW
32.00
MARKET CAP
6.07B
P/E (TTM)
79.19
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Bullish on Top Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), REPRO-MED Systems (KRMD)
TipRanks · 10h ago
Weekly Report: what happened at KNSA last week (0803-0807)?
Weekly Report · 3d ago
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)?
Simply Wall St · 4d ago
Weekly Report: what happened at KNSA last week (0727-0731)?
Weekly Report · 08/03 09:34
Kiniksa Pharmaceuticals International (KNSA) After Raised 2026 Guidance And Strong Q2 Results Looks Fully Valued
Simply Wall St · 08/01 16:28
Insider Shake-Up at Kiniksa Pharmaceuticals Sparks Investor Buzz
TipRanks · 08/01 02:02
Kiniksa Pharmaceuticals (KNSA) Stock Cools As Raised Guidance Meets ARCALYST Reliance
Simply Wall St · 07/30 20:18
Kiniksa Pharmaceuticals Price Target Raised to $90.00/Share From $75.00 by Goldman Sachs
Dow Jones · 07/30 18:53
More
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Webull offers Kiniksa Pharmaceuticals Internatinl, PLC stock information, including NASDAQ: KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.